Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Annual COVID-19 vaccines likely, according to Pfizer CEO

By Brian Buntz | April 15, 2021

Pfizer-BioNTechThe public may require annual vaccines to protect against SARS-CoV-2, Pfizer (NYSE:PFE) CEO Albert Bourla said today. 

“It is extremely important to suppress the pool of people that can be susceptible to the virus,” Bourla said in a CNBC interview. 

While the details of Pfizer-BioNTech boosters are not yet clear, COVID-19 boosters will likely be based on an mRNA platform. 

Adenovirus-vectored vaccines from AstraZeneca and Johnson & Johnson are currently in limited use, given concerns that they could cause rare but serious blood clotting problems. 

The mRNA vaccines from Moderna and Pfizer/BioNTech also have a head start, and U.S. officials expect 600 million doses of the vaccines to be delivered by the end of July. 

It will be “a stretch for adenoviral-vector vaccines to have any material uptake,” in the U.S., said Navin Jacob, a senior equity research analyst at UBS. “And you can’t really give boosters with the adenoviral-vector vaccines because of the potential for attenuation of efficacy because of antibodies that are created against the vector,” Jacob added.

Early data from Pfizer and Moderna suggest that mRNA vaccines offer a durable immune response with antibodies persisting at least six months after vaccination. 

Pfizer and Moderna are both developing versions of their vaccines to optimize protection against more-transmissible variants. 

Moderna CEO Stéphane Bancel recently announced that the company was exploring developing a vaccine to protect against both COVID-19 and influenza. 

Speaking broadly about immunity from vaccines, Dr. Shahrokh Shabahang, CIO of Aditx Therapeutics, said there is “no reason for us to think that SARS-CoV-2 defies all rules of infectious diseases and immunity.” 

While the public may be familiar with flu vaccines, comparing immunity to SARS-CoV-2 and the flu “confuses the issue,” Shabahang said. “Flu is not one disease. It’s a syndrome made up of multiple symptoms caused by multiple infectious agents,” he added. 

In addition to the four flu strains (A, B, C and D), other viruses, including HIV, can cause flu-like illness. 

The public can confuse the seasonal nature of flu infections and the variable risk SARS-CoV-2 variants pose. 

Ultimately, though, more data are needed to understand the durability of immunity from SARS-CoV-2, COVID-19 vaccines and how SARS-CoV-2 variants will inform vaccination strategies. 

“The only way to really understand if someone has long-term immunity is looking at memory cells,” Shabahang said. 

“If we’re just looking at antibody levels or saying we need to give boosters every year based on the fact that we’re doing that for flu or the fact that antibody levels wane over time, that’s not a good way to evaluate long term immunity,” Shabahang concluded.


Filed Under: Infectious Disease
Tagged With: AstraZeneca plc, BioNTech, coronavirus, covid-19, COVID-19 vaccine, COVID-19 vaccine trial, COVID-19 vaccines, Pfizer, SARS-CoV-2
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

covid-19 vaccine
FDA COVID booster pullback jolts vaccine stocks before gains cool
Coronavirus Covid-19 background - 3d rendering
Pregnancy associated with less long COVID: Researchers call for studies on protective biology
How technology advances are helping scientists unlock the mysteries of zoonotic diseases
Novel coronovirus
Advances in next generation vaccine development for SARS-CoV-2
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE